Literature DB >> 8355064

Comparability of FDG PET studies in probable Alzheimer's disease.

K Herholz1, D Perani, E Salmon, G Franck, F Fazio, W D Heiss, D Comar.   

Abstract

Results of studies with positron emission tomography (PET) of 18F-2-fluoro-2-deoxy-D-glucose (FDG) in patients with probable Alzheimer's disease (AD) were compared among three European centers with different PET scanners (in-plane resolution ranging between 6.75 mm and 9.2 mm). A ratio of glucose metabolism in the most typically affected regions over the least typically affected regions was calculated to quantitatively analyze the characteristic pattern of AD. Diagnostic accuracy of this composite ratio was high (95.8%) and was superior to that of most ratios derived from single regions. Correspondingly, there was a consistent, highly significant difference between patients (mean ratio 0.77 +/- 0.11) and normals (mean 0.99 +/- 0.04) without significant differences among laboratories. Possible small effects of rate constant variation and region size were analyzed by computer simulation. The results demonstrate that a common investigation protocol may yield FDG PET data in different laboratories that are closely comparable in spite of differences between scanners and imaging equipment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8355064

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

Review 1.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

2.  Demonstration of decreased posterior cingulate perfusion in mild Alzheimer's disease by means of H215O positron emission tomography.

Authors:  K Ishii; M Sasaki; S Yamaji; S Sakamoto; H Kitagaki; E Mori
Journal:  Eur J Nucl Med       Date:  1997-06

3.  Voxel-based analysis of confounding effects of age and dementia severity on cerebral metabolism in Alzheimer's disease.

Authors:  E Salmon; F Collette; C Degueldre; C Lemaire; G Franck
Journal:  Hum Brain Mapp       Date:  2000-05       Impact factor: 5.038

4.  Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET.

Authors:  Lisa Mosconi; Susan De Santi; Yi Li; Juan Li; Jiong Zhan; Wai Hon Tsui; Madhu Boppana; Alberto Pupi; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-11-26       Impact factor: 9.236

Review 5.  Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease.

Authors:  Bradford C Dickerson; Reisa A Sperling
Journal:  NeuroRx       Date:  2005-04

Review 6.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

7.  Brain SPECT in subtypes of mild cognitive impairment. Findings from the DESCRIPA multicenter study.

Authors:  Flavio Nobili; Giovanni B Frisoni; Florence Portet; Frans Verhey; Guido Rodriguez; Anna Caroli; Jacques Touchon; Piero Calvini; Silvia Morbelli; Fabrizio De Carli; Ugo P Guerra; Laura A Van de Pol; Pieter-Jelle Visser
Journal:  J Neurol       Date:  2008-08-01       Impact factor: 4.849

8.  The neural correlates of naming and fluency deficits in Alzheimer's disease: an FDG-PET study.

Authors:  Rebecca J Melrose; Olivia M Campa; Dylan G Harwood; Sheryl Osato; Mark A Mandelkern; David L Sultzer
Journal:  Int J Geriatr Psychiatry       Date:  2009-08       Impact factor: 3.485

9.  Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Jessica B S Langbaum; Kewei Chen; Wendy Lee; Cole Reschke; Dan Bandy; Adam S Fleisher; Gene E Alexander; Norman L Foster; Michael W Weiner; Robert A Koeppe; William J Jagust; Eric M Reiman
Journal:  Neuroimage       Date:  2009-01-21       Impact factor: 6.556

10.  HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern.

Authors:  R Mielke; U Pietrzyk; A Jacobs; G R Fink; A Ichimiya; J Kessler; K Herholz; W D Heiss
Journal:  Eur J Nucl Med       Date:  1994-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.